Free Access
Med Sci (Paris)
Volume 28, Number 4, Avril 2012
Page(s) 339 - 340
Section Éditorial
Published online 25 April 2012
  1. Sinkovics JG, Horvath JC. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp 2008 ; 56 (suppl 1) : S3–S59. [Google Scholar]
  2. Garber K. China approves world’s first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006 ; 98 : 298–300. [CrossRef] [PubMed] [Google Scholar]
  3. Stanford MM, Bell JC, Vähä-Koskela MJV. Novel oncolytic viruses: riding high on the next wave? Cytokine Growth Factor Rev 2010 ; 21 : 177–183. [CrossRef] [PubMed] [Google Scholar]
  4. Koppers-Lalic D, Hoeben RC. Non-human viruses developed as therapeutic agent for use in humans. Rev Med Virol 2011 ; 21 : 227–239. [CrossRef] [PubMed] [Google Scholar]
  5. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008 ; 6 : 529–540. [CrossRef] [PubMed] [Google Scholar]
  6. Russell SJ, Peng K. Measles virus for cancer therapy. Curr Top Microbiol Immunol 2009 ; 330 : 213–411. [CrossRef] [PubMed] [Google Scholar]
  7. Touchefeu Y, Schick U, Harrington KJ. Le virus de la rougeole : un futur traitement en cancérologie ? Med Sci (Paris) 2012 ; 28 : 388–394. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  8. Verheije MH, Rottier PJM. Retargeting of viruses to generate oncolytic agents. Adv Virol 2012 ; 2012 : 1–15. [CrossRef] [Google Scholar]
  9. Liu C, Hasegawa K, Russell SJ, et al. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 2009 ; 69 : 1128–1141. [CrossRef] [PubMed] [Google Scholar]
  10. Noyce RS, Bondre DG, Ha MN, et al. Tumor cell marker PVRL4 (Nectin 4) is an epithelial cell receptor for measles virus. PloS Pathog 2011 ; 7 : e1002240. [CrossRef] [PubMed] [Google Scholar]
  11. Mühlebach MD, Mateo M, Sinn PL, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011 ; 480 : 530–533. [PubMed] [Google Scholar]
  12. Mateo M, Lopez M. Nectine-4, une protéine clé pour la transmission du virus de la rougeole. Med Sci (Paris) 2012 ; 28 : 363–365. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  13. Leonard VHJ, Hodge G, Reyes-del Valle J, et al. Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. J Virol 2010 ; 84 : 3413–3420. [CrossRef] [PubMed] [Google Scholar]
  14. Bell JC, Kirn D. MicroRNAs fine-tune oncolytic viruses. Nat Biotechnol 2008 ; 26 : 1346–1348. [CrossRef] [PubMed] [Google Scholar]
  15. Leber MF, Bossow S, Leonard VH, et al. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. Mol Ther 2009 ; 19 : 1097–1106. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.